151751-Najiba-Chargi

185 Systemic therapy: skeletal muscle mass and chemoradiotherapy Table 1. (Continued) Characteristic Total N=343 Without low SMM n=144 41.98% With Low SMM n=199 58.01% Without DLT n=189 55.1% With DLT n=154 44.90% N, % Mean, SD N, % Mean, SD N, % Mean, SD p N, % Mean, SD N, % Mean, SD p Serum creatinine (mmol/L) 69.9(15.6) 76.77 (14.7) 65.13 (14.5) <0.01 69.97(15.8) 70.0 (15.5) 0.98 Tumor site Oral cavity Oropharynx Nasopharynx Hypopharynx Larynx Paranasal sinus 87 (25.4) 129 (37.6) 45 (13.1) 49 (14.3) 18 (5.2) 11 (3.2) 29 (33.3) 51 (39.5) 27 (60.0) 22 (15.3) 8 (44.4) 5 (45.5) 58 (66.7) 78 (60.5) 18 (40.0) 26 (13.1) 10 (55.6) 6 (54.5) 0.12 51 (58.6) 70 (54.3) 24 (53.3) 27 (55.1) 10 (55.6) 6 (54.5) 36 (41.4) 59 (45.7) 21 (46.7) 22 (44.9) 8 (44.4) 5 (45.5) 0.93 TNM stage III IV 59 (17.2) 284 (82.8) 26 (44.1) 118 (41.5) 33 (55.9) 166 (58.5) 0.77 32 (54.2) 157 (55.3) 27 (45.8) 127 (44.7) 0.89 CRT Primary Postoperative 274 (79.9) 69 (20.1) 123 (44.9) 21 (30.4) 151 (55.1) 48 (69.6) 0.04 154 (56.2) 35 (50.7) 120 (43.8) 34 (49.3) 0.42 Cisplatin dose (mg/kg LBM) (median, IQR) 8.1 (4.2-11.8) 7.4 (3.6) 9.0 (4.3) <0.01 10.0 (4.4) 6.3 (2.6) <0.01 Figure 1. Boxplot of the amount of LSMI (cm 2 /m 2 ) in patients who have not experienced cisplatin DLT and patients who experienced cisplatin DLT 10